A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms MCL-004
- Sponsors Celgene Corporation
- 24 Jan 2017 Status changed to completed.
- 06 Dec 2016 Status changed from recruiting to active, no longer recruiting,according to the results published at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.